Neurogesx (NGSX) 0.0075 $NGSX
OTC Signal Daily Stock Watch - NeurogesX, Inc., (OTC:NGSX)
WorldStockWire - Wed Sep 04, 6:15PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2012
M2 - Fri Aug 02, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/93dth7/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for peripheral neuropathy (sensory neuropathy), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for peripheral neuropathy (sensory neuropathy). The information is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for peripheral neuropathy (sensory neuropathy). - A review of the peripheral neuropathy (sensory neuropathy) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the peripheral neuropathy (sensory neuropathy) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Peripheral Neuropathy (Sensory Neuropathy) Overview Therapeutics Development An Overview of Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) Companies Involved in Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Development Drug Profiles Featured News & Press Releases Appendix Companies Mentioned - Allon Therapeutics Inc - Neuren Pharmaceuticals Limited - NeurogesX, Inc - NsGene A/S For more information visit http://www.researchandmarkets.com/research/93dth7/peripheral
Postherpetic Neuralgia - Pipeline Review, H2 2012
M2 - Thu Aug 01, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f66v5t/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. It also provides information on the therapeutic development for Postherpetic Neuralgia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Postherpetic Neuralgia. - A review of the Postherpetic Neuralgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Postherpetic Neuralgia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Postherpetic Neuralgia Overview Therapeutics Development An Overview of Pipeline Products for Postherpetic Neuralgia Companies Involved in Postherpetic Neuralgia Therapeutics Development Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix Companies Mentioned: - Allergan, Inc - Amgen Inc - Arcion Therapeutics - Bial - Portela & Ca, S.A - Bristol-Myers Squibb Company - Celtic Pharmaceutical Holdings L.P - DURECT Corporation - Daewoong Pharmaceutical Co - EpiCept Corporation - Kyowa Hakko Kirin Co - NeurogesX, Inc - SantoSolve AS - Spinifex Pharmaceuticals Pty Limited - TheraQuest Biosciences, LLC - Valeant Pharmaceuticals International - Winston Pharmaceuticals - Xenon Pharmaceuticals Inc For more information visit http://www.researchandmarkets.com/research/f6...stherpetic
Peripheral Neuropathic Pain - Pipeline Review, H1 2013
M2 - Wed Jul 17, 10:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/94lzdl/peripheral) has announced the addition of the "Peripheral Neuropathic Pain - Pipeline Review, H1 2013" report to their offering. 'Peripheral Neuropathic Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peripheral Neuropathic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral Neuropathic Pain. Scope - A snapshot of the global therapeutic scenario for Peripheral Neuropathic Pain. - A review of the Peripheral Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature o
Acorda Expands Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 11, 5:20PM CDT
The company acquired Qutenza and NP-1998 from NeurogesX, Inc.
Acorda Therapeutics Inc acquires two neuropathic pain assets for approximately USD8m from NeurogesX Inc
M2 - Wed Jul 10, 4:59AM CDT
Biotechnology company Acorda Therapeutics Inc (Nasdaq:ACOR) revealed on Tuesday that it has completed its acquisition of two neuropathic pain management assets, Qutenza and NP-1998, from NeurogesX Inc (OTC Markets:NGSX).
SCR, LDK, FIG, NGSX, ESSA, DGICA Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Feb 08, 6:59AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Score Media Inc (NYSE:SCR), LDK Solar Co Ltd (NYSE:LDK), Fortress Investment Group LLC (NYSE:FIG), NeurogesX Inc (NASDAQ:NGSX), ESSA Bancorp Inc (NASDAQ:ESSA), Donegal Group Inc (NASDAQ
GICA) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
OMPI, GLUU, NGSX, MWA, REXX, CVGI Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Jan 08, 6:53AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Obagi Medical Products Inc (NASDAQ:OMPI), Glu Mobile Inc (NASDAQ:GLUU), NeurogesX Inc (NASDAQ:NGSX), Mueller Water Products Inc (NYSE:MWA), Rex Energy Corp (NASDAQ:REXX), Commercial Vehicle Group Inc (NASDAQ:CVGI) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
OTC Signal Daily Stock Watch - NeurogesX, Inc., (OTC:NGSX)
WorldStockWire - Wed Sep 04, 6:15PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2012
M2 - Fri Aug 02, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/93dth7/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for peripheral neuropathy (sensory neuropathy), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for peripheral neuropathy (sensory neuropathy). The information is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for peripheral neuropathy (sensory neuropathy). - A review of the peripheral neuropathy (sensory neuropathy) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the peripheral neuropathy (sensory neuropathy) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Peripheral Neuropathy (Sensory Neuropathy) Overview Therapeutics Development An Overview of Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) Companies Involved in Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Development Drug Profiles Featured News & Press Releases Appendix Companies Mentioned - Allon Therapeutics Inc - Neuren Pharmaceuticals Limited - NeurogesX, Inc - NsGene A/S For more information visit http://www.researchandmarkets.com/research/93dth7/peripheral
Postherpetic Neuralgia - Pipeline Review, H2 2012
M2 - Thu Aug 01, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f66v5t/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. It also provides information on the therapeutic development for Postherpetic Neuralgia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Postherpetic Neuralgia. - A review of the Postherpetic Neuralgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Postherpetic Neuralgia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Postherpetic Neuralgia Overview Therapeutics Development An Overview of Pipeline Products for Postherpetic Neuralgia Companies Involved in Postherpetic Neuralgia Therapeutics Development Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix Companies Mentioned: - Allergan, Inc - Amgen Inc - Arcion Therapeutics - Bial - Portela & Ca, S.A - Bristol-Myers Squibb Company - Celtic Pharmaceutical Holdings L.P - DURECT Corporation - Daewoong Pharmaceutical Co - EpiCept Corporation - Kyowa Hakko Kirin Co - NeurogesX, Inc - SantoSolve AS - Spinifex Pharmaceuticals Pty Limited - TheraQuest Biosciences, LLC - Valeant Pharmaceuticals International - Winston Pharmaceuticals - Xenon Pharmaceuticals Inc For more information visit http://www.researchandmarkets.com/research/f6...stherpetic
Peripheral Neuropathic Pain - Pipeline Review, H1 2013
M2 - Wed Jul 17, 10:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/94lzdl/peripheral) has announced the addition of the "Peripheral Neuropathic Pain - Pipeline Review, H1 2013" report to their offering. 'Peripheral Neuropathic Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peripheral Neuropathic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral Neuropathic Pain. Scope - A snapshot of the global therapeutic scenario for Peripheral Neuropathic Pain. - A review of the Peripheral Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature o
Acorda Expands Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 11, 5:20PM CDT
The company acquired Qutenza and NP-1998 from NeurogesX, Inc.
Acorda Therapeutics Inc acquires two neuropathic pain assets for approximately USD8m from NeurogesX Inc
M2 - Wed Jul 10, 4:59AM CDT
Biotechnology company Acorda Therapeutics Inc (Nasdaq:ACOR) revealed on Tuesday that it has completed its acquisition of two neuropathic pain management assets, Qutenza and NP-1998, from NeurogesX Inc (OTC Markets:NGSX).
SCR, LDK, FIG, NGSX, ESSA, DGICA Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Feb 08, 6:59AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Score Media Inc (NYSE:SCR), LDK Solar Co Ltd (NYSE:LDK), Fortress Investment Group LLC (NYSE:FIG), NeurogesX Inc (NASDAQ:NGSX), ESSA Bancorp Inc (NASDAQ:ESSA), Donegal Group Inc (NASDAQ
GICA) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: OMPI, GLUU, NGSX, MWA, REXX, CVGI Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Jan 08, 6:53AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Obagi Medical Products Inc (NASDAQ:OMPI), Glu Mobile Inc (NASDAQ:GLUU), NeurogesX Inc (NASDAQ:NGSX), Mueller Water Products Inc (NYSE:MWA), Rex Energy Corp (NASDAQ:REXX), Commercial Vehicle Group Inc (NASDAQ:CVGI) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
